UnknownNot Applicable

Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up

France250 participantsStarted 2021-03-15

Plain-language summary

This study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (T1D) diagnosis, and their incidence rate during follow-up, for children and adolescents. It also aims to describe the characteristics of the pediatric cohort followed since 2014 for type 1 diabetes by one of France's centers of reference for paediatric diabetes.

Who can participate

Age range6 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with type 1 diabetes diagnosed with the following criteria: (i) Classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration ≥11.1 mmol/L (200 mg/dl), or (ii) fasting plasma glucose ≥7.0 mmol/l (≥126 mg/dl) ; and (iii) presence of diabetes associated autoantibodies : ICA, GAD, IA2, IAA and/or ZnT8 * age \< 18 years old at type 1 diabetes diagnostic * type 1 diabetes diagnosed between 2014-01-01 and 2021-02-01 Exclusion Criteria: * type 1 diabetes diagnostic not certain

What they're measuring

Number of additional autoimmune diseases at type 1 diabetes diagnosis

Timeframe: up to 3 weeks after type 1 diabetes diagnosis

Type of additional autoimmune diseases at type 1 diabetes diagnosis

Timeframe: up to 3 weeks after type 1 diabetes diagnosis

Trial details

NCT IDNCT04789993

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-03-31

View on ClinicalTrials.gov More Type 1 Diabetes trials